4-bromo-N-methyl-2-nitro-1-naphthylamine | 80429-48-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 4-bromo-N-methyl-2-nitro-1-naphthylamine
• 英文别名: 4-bromo-1-methylamino-2-nitronaphthalene；4-bromo-N-methyl-2-nitronaphthalen-1-amine
• CAS: 80429-48-7
• 化学式: C₁₁H₉BrN₂O₂
• 分子量: 281.109
• InChiKey: WTUKHSIDGWNWSV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-bromo-N-methyl-2-nitro-1-naphthylamine 在 palladium on activated charcoal 氢气 、 三乙胺 作用下， 以 甲醇 为溶剂， 反应 1.5h， 以91%的产率得到N1-甲基-1,2-萘二胺
  参考文献：
  名称：

  Anti-hypertensives: 1-alkyl-2-arylpiperazinoethyl-1H-naphth[1,2-d]imidazoles

  摘要：

  DOI：

  10.1016/0223-5234(87)90053-5
• 作为产物：
  描述：

  1-甲氧基萘 在 N-溴代丁二酰亚胺(NBS) 、 硫酸 、 硝酸 作用下， 以 四氯化碳 、 乙酸酐 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.17h， 生成 4-bromo-N-methyl-2-nitro-1-naphthylamine
  参考文献：
  名称：

  Anti-hypertensives: 1-alkyl-2-arylpiperazinoethyl-1H-naphth[1,2-d]imidazoles

  摘要：

  DOI：

  10.1016/0223-5234(87)90053-5

文献信息

• Cycloalkyl or benzyl-6-substituted-quinoxalinediones
  申请人：A/S Ferrosan

  公开号：US04948794A1

  公开（公告）日：1990-08-14

  Heterocyclic dihydroxyquinoxaline compounds having the formula ##STR1## wherein R.sup.1 is C.sub.1-12 -alkyl, which may optionally be substituted by hydroxy, formyl, carboxy, carboxylic esters, amides or amines, C.sub.3-8 -cycloalkyl, aryl, aralkyl; and wherein R.sup.6 is, hydrogen, halogen, CN, CF.sub.3, NO.sub.2, or OR', wherein R' is C.sub.1-4 -alkyl and R.sup.5, R.sup.7 and R.sup.8 is hydrogen, provided R.sup.6 is not CF.sub.3, OCH.sub.3, NO.sub.2, C.sup.1 or Br when R.sup.1 is CH.sub.3 ; or R.sup.6 and R.sup.7 independently are NO.sub.2, halogen, CN, CF.sub.3, or OR', wherein R' is C.sub.1-4 -alkyl, and R.sup.5 and R.sup.8 are each hydrogen; or R.sup.5 and R.sup.6 together form a further fused aromatic ring, which may be substituted with halogen, NO.sub.2, CN, CF.sub.3 or OR', wherein R' is C.sub.1-4 -alkyl, and R.sup.7 and R.sup.8 independently are hydrogen, halogen, CN, CF.sub.3, NO.sub.2 or OR', wherein R' is C.sub.1-4 -alkyl; or R.sup.7 and R.sup.8 together form a further fused aromatic ring, which may be substituted with halogen, NO.sub.2, CN, CF.sub.3 or OR', wherein R' is C.sub.1-4 -alkyl, and R.sup.5 and R.sup.6 independently are hydrogen, halogen, CN, CF.sub.3, NO.sub.2 or OR', wherein R' is C.sub.1-4 -alkyl. The invention also relates to a method of preparing the compounds, pharmaceutical compositions thereof, and their use. The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters, particularly the quisqualate receptors, and especially as neuroleptics.

  含有以下化学式的杂环二羟喹喔啉化合物，其中R.sup.1是C.sub.1-12-烷基，可以选择性地被羟基、甲酰基、羧基、羧酸酯、酰胺或胺取代，也可以是C.sub.3-8-环烷基、芳基、芳基烷基；而R.sup.6是氢、卤素、CN、CF.sub.3、NO.sub.2或OR'，其中R'是C.sub.1-4-烷基，而R.sup.5、R.sup.7和R.sup.8是氢，只要R.sup.6不是CF.sub.3、OCH.sub.3、NO.sub.2、C.sup.1或Br当R.sup.1是CH.sub.3时；或R.sup.6和R.sup.7独立地是NO.sub.2、卤素、CN、CF.sub.3或OR'，其中R'是C.sub.1-4-烷基，而R.sup.5和R.sup.8各自是氢；或R.sup.5和R.sup.6一起形成另外一个融合的芳香环，该环可以被卤素、NO.sub.2、CN、CF.sub.3或OR'取代，其中R'是C.sub.1-4-烷基，而R.sup.7和R.sup.8独立地是氢、卤素、CN、CF.sub.3、NO.sub.2或OR'，其中R'是C.sub.1-4-烷基；或R.sup.7和R.sup.8一起形成另外一个融合的芳香环，该环可以被卤素、NO.sub.2、CN、CF.sub.3或OR'取代，其中R'是C.sub.1-4-烷基，而R.sup.5和R.sup.6独立地是氢、卤素、CN、CF.sub.3、NO.sub.2或OR'，其中R'是C.sub.1-4-烷基。该发明还涉及制备这些化合物的方法、其药物组合物以及它们的用途。这些化合物在治疗由兴奋性神经递质过度活跃引起的症状方面很有用，特别是在治疗quisqualate受体引起的情况下，尤其作为神经精神药物。
• Naphth[1,2-d]imidazoles
  申请人：Gruppo Lepetit S.p.A.

  公开号：US04461894A1

  公开（公告）日：1984-07-24

  Naphth[1,2-d]imidazoles and naphth[2,1-d]oxazoles of formula ##STR1## wherein R and R.sub.1 are hydrogen, halogen, alkyl or alkoxy, R.sub.2 is hydrogen or halogen and A is one of the following moieties ##STR2## wherein R.sub.3 is alkyl, cycloalkyl, or a --(CH.sub.2).sub.n NR.sub.5 R.sub.6 group in which n is 1, 2 or 3, R.sub.5 is hydrogen or alkyl, R.sub.6 is alkyl or R.sub.5 and R.sub.6 taken together with the adjacent nitrogen atom are a 4- to 7-membered saturated hetero ring which may contain a further hetero atom and optionally may be substituted, e.g., with phenyl or substituted phenyl, R.sub.4 is hydrogen, alkyl, cycloalkyl or a --(CH.sub.2).sub.n NR.sub.5 R.sub.6 group, provided that one of R.sub.3 and R.sub.4 is a --(CH.sub.2).sub.n --NR.sub.5 R.sub.6 group, and R.sub.7 is --(CH.sub.2).sub.n --NR.sub.5 R.sub.6, or a pharmaceutically-acceptable acid addition salt thereof. They are made by contacting a corresponding naphth[1,2-d]imidazole or a naphth[2,1-d]oxazole wherein one of R.sub.3 and R.sub.4 or R.sub.7 is a --(CH.sub.2).sub.n X group wherein X is the residue of a reactive ester with an appropriate amine of the formula HNR.sub.5 R.sub.6 in the presence of an acid acceptor. The new compounds are useful as CNS-depressant agents.

  Naphth [1,2-d]咪唑和naphth [2,1-d]噁唑的化学式为##STR1##其中R和R.sub.1是氢，卤素，烷基或烷氧基，R.sub.2是氢或卤素，A是以下之一的基团##STR2##其中R.sub.3是烷基，环烷基或--(CH.sub.2).sub.n NR.sub.5 R.sub.6基团，其中n为1,2或3，R.sub.5是氢或烷基，R.sub.6是烷基或R.sub.5和与其相邻的氮原子一起形成4-至7-成员饱和杂环，其中可能含有进一步的杂原子并且可以选择性地被取代，例如，苯基或取代苯基，R.sub.4是氢，烷基，环烷基或--(CH.sub.2).sub.n NR.sub.5 R.sub.6基团，只要R.sub.3和R.sub.4中的一个是--(CH.sub.2).sub.n --NR.sub.5 R.sub.6基团，R.sub.7是--(CH.sub.2).sub.n --NR.sub.5 R.sub.6，或其药学上可接受的酸加成盐。它们是通过将相应的naphth [1,2-d]咪唑或naphth [2,1-d]噁唑与其中一个R.sub.3和R.sub.4或R.sub.7是--(CH.sub.2).sub.n X基团（其中X是反应性酯的残基）的适当胺在酸受体存在下进行接触制备的。这些新化合物可用作中枢神经系统抑制剂。
• Quinoxaline compounds and their preparation and use
  申请人：NOVO NORDISK A/S

  公开号：EP0315959A2

  公开（公告）日：1989-05-17

  Heterocyclic dihydroxyquinoxaline compounds having the formula wherein R¹ is C₁₋₁₂-alkyl, which may obtionally be substituted by hydroxy, formyl, carboxy, carboxylic esters, amides or ami­nes, C₃₋₈-cycloalkyl, aryl, aralkyl; and wherein R⁶ is, hy­drogen, halogen, CN, CF₃, NO₂, or OR′, wherein R′ is C₁₋₄-­alkyl and R⁵, R⁷ and R⁸ is hydrogen, provided R⁶ is not CF₃, OCH₃, NO₂, CL or Br when R¹ is CH₃; or R⁶ and R⁷ independently are NO₂, halogen, CN, CF₃, or OR′, wherein R′ is C₁₋₄-alkyl, and R⁵ and R⁸ are each hydrogen; or R⁵ and R⁶ together form a further fused aromatic ring, which may be substituted with halogen, NO₂, CN, CF₃ or OR′, wherein R′ is C₁₋₄-alkyl, and R⁷ and R⁸ independently are hydrogen, halogen, CN, CF₃, NO₂ or OR′ wherein R′ is C₁₋₄-alkyl; or R⁷ and R⁸ together form a further fused aromatic ring, which may be substituted with halogen, NO₂, CN, CF₃ or OR′, wherein R′ is C₁₋₄-alkyl, and R⁵ and R⁶ independently are hydrogen, halogen, CN, CF₃, NO₂ or OR′, wherein R′ is C₁₋₄-alkyl. The invention also relates to a method of preparing the compounds, pharmaceutical compositions thereof, and their use. The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters, particularly the quisqualate receptors, and especially as neuroleptics.

  具有以下式子的杂环二羟基喹喔啉化合物 其中 R¹ 是 C₁₋₁₂-烷基，可被羟基、甲酰基、羧基、羧酸酯、酰胺或胺、C₃₋₈-环烷基、芳基、芳烷基取代；其中 R⁶ 是氢、卤素、CN、CF₃、NO₂ 或 OR′，其中 R′ 是 C₁₋₄-烷基和 R⁵、R⁷ 和 R⁸ 是氢，条件是 R⁶ 不是 CF₃、OCH₃、NO₂、CL 或 Br（当 R¹ 是 CH₃ 时）；或 R⁶ 和 R⁷ 独立地为 NO₂、卤素、CN、CF₃ 或 OR′，其中 R′为 C₁₋₄-烷基，且 R⁵ 和 R⁸ 均为氢；或 R⁵ 和 R⁶ 共同形成另一个可被卤素、NO₂、CN、CF₃ 或 OR′取代的融合芳环、其中 R′为 C₁₄-烷基，且 R⁷ 和 R⁸ 独立地为氢、卤素、CN、CF₃、NO₂ 或 OR′，其中 R′为 C₁₄-烷基；或 R⁷ 和 R⁸ 共同形成另一个可被卤素、NO₂、CN、CF₃ 或 OR′取代的融合芳环、其中 R′为 C₁₋₄-烷基，且 R⁵ 和 R⁶ 独立地为氢、卤素、CN、CF₃、NO₂ 或 OR′，其中 R′为 C₁₋₄-烷基。 本发明还涉及化合物的制备方法、其药物组合物及其用途。 本发明的化合物可用于治疗兴奋性神经递质，特别是喹乙醇受体亢进引起的适应症，尤其可用作神经抑制剂。
• SALE, A. O.;TOLA, E.
  作者：SALE, A. O.、TOLA, E.

  DOI：——

  日期：——
• SALE, AMEDEO OMODEI;TOIA, EMILIO
  作者：SALE, AMEDEO OMODEI、TOIA, EMILIO

  DOI：——

  日期：——